18,961 research outputs found
Memecylon pseudomegacarpum M.Hughes (Melastomataceae), a new species of tree from Peninsular Malaysia
No full textA new species, Memecylon pseudomegacarpum (Melastomataceae), is described from southern Peninsular Thailand, Peninsular Malaysia and Singapore. This taxon was previously known under the misapplied name M. megacarpum, which is now considered endemic to Borneo. Memecylon pseudomegacarpum sp. nov. differs from M. megacarpum in having smaller leaves (8–)10.5–17(–22.5) cm rather than (10–)17–28(–35) cm long, with an elliptic lamina (not lanceolate) with a raised mid-rib (not sunken) and a marginal vein which is 2–4 mm from the margin (not 5–12 mm). Both species have similar flowers and share large (c. 15 mm diameter) globose fruits
Link stability estimation based on link connectivity changes in mobile ad-hoc networks
No full textDear Wang,
Re: Link Stability Estimation Based on Link Connectivity Changes in Mobile Ad-hoc Networks
I have not been able to assess if this is an author version peer-reviewed or is it an author version non peer reviewed. Could you please clarify this so I can proceed to add your paper to Spiral. Spiral digital repository only accept peer-reviewed papers.
30/11/12 author has confirmed peer reviewe
Hughes Cookout, AD
No full textPeople gathered inside the Hughes Supply warehouse for a party, seated at long tables enjoying a cookout.https://digitalcommons.usf.edu/gandy_commercial/10940/thumbnail.jp
[Plane]
No full textFrom Sleeve: Taubman Auto Ad. N450.Title supplied by cataloger.Positive digital file from original glass negative.minor scratches in emulsio
[Window display at jewelry store]
No full textFrom Sleeve: Window Display - jewelry ad. N67.Title supplied by cataloger.Positive digital file from original glass negative.slight peeling of emulsion along sid
[Barrel of King syrup]
No full textFrom Sleeve: Mangels Herold ad - syrup. N62a.Title supplied by cataloger.Positive digital file from original glass negative.slight chipping of emulsion in bottom corner [camera to right of barrel
[Freight car with sign for American Wholesale Corp.]
No full textFrom Sleeve: Ad sign. Freight car with sign. American Wholesale Corp. A301.Title supplied by cataloger.Positive digital file from original glass negative.Plate broken in upper left corner and pasted back together, chips along top edg
Cerebral atrophy in mild cognitive impairment and Alzheimer disease: rates and acceleration.
No full textOBJECTIVE: To quantify the regional and global cerebral atrophy rates and assess acceleration rates in healthy controls, subjects with mild cognitive impairment (MCI), and subjects with mild Alzheimer disease (AD). METHODS: Using 0-, 6-, 12-, 18-, 24-, and 36-month MRI scans of controls and subjects with MCI and AD from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, we calculated volume change of whole brain, hippocampus, and ventricles between all pairs of scans using the boundary shift integral. RESULTS: We found no evidence of acceleration in whole-brain atrophy rates in any group. There was evidence that hippocampal atrophy rates in MCI subjects accelerate by 0.22%/year2 on average (p = 0.037). There was evidence of acceleration in rates of ventricular enlargement in subjects with MCI (p = 0.001) and AD (p < 0.001), with rates estimated to increase by 0.27 mL/year2 (95% confidence interval 0.12, 0.43) and 0.88 mL/year2 (95% confidence interval 0.47, 1.29), respectively. A post hoc analysis suggested that the acceleration of hippocampal loss in MCI subjects was mainly driven by the MCI subjects that were observed to progress to clinical AD within 3 years of baseline, with this group showing hippocampal atrophy rate acceleration of 0.50%/year2 (p = 0.003). CONCLUSIONS: The small acceleration rates suggest a long period of transition to the pathologic losses seen in clinical AD. The acceleration in hippocampal atrophy rates in MCI subjects in the ADNI seems to be driven by those MCI subjects who concurrently progressed to a clinical diagnosis of AD
DOMINO-AD protocol : donepezil and memantine in moderate to severe Alzheimer's disease – a multicentre RCT
No full textBackground: Alzheimer's disease (AD) is the commonest cause of dementia. Cholinesterase
inhibitors, such as donepezil, are the drug class with the best evidence of efficacy, licensed for mild
to moderate AD, while the glutamate antagonist memantine has been widely prescribed, often in
the later stages of AD. Memantine is licensed for moderate to severe dementia in AD but is not
recommended by the England and Wales National Institute for Health and Clinical Excellence.
However, there is little evidence to guide clinicians as to what to prescribe as AD advances; in
particular, what to do as the condition progresses from moderate to severe. Options include
continuing cholinesterase inhibitors irrespective of decline, adding memantine to cholinesterase
inhibitors, or prescribing memantine instead of cholinesterase inhibitors. The aim of this trial is to
establish the most effective drug option for people with AD who are progressing from moderate
to severe dementia despite treatment with donepezil.
Method: DOMINO-AD is a pragmatic, 15 centre, double-blind, randomized, placebo controlled
trial. Patients with AD, currently living at home, receiving donepezil 10 mg daily, and with
Standardized Mini-Mental State Examination (SMMSE) scores between 5 and 13 are being recruited.
Each is randomized to one of four treatment options: continuation of donepezil with memantine
placebo added; switch to memantine with donepezil placebo added; donepezil and memantine
together; or donepezil placebo with memantine placebo. 800 participants are being recruited and
treatment continues for one year. Primary outcome measures are cognition (SMMSE) and activities
of daily living (Bristol Activities of Daily Living Scale). Secondary outcomes are non-cognitive
dementia symptoms (Neuropsychiatric Inventory), health related quality of life (EQ-5D and
DEMQOL-proxy), carer burden (General Health Questionnaire-12), cost effectiveness (using
Client Service Receipt Inventory) and institutionalization. These outcomes are assessed at baseline,
6, 18, 30 and 52 weeks. All participants will be subsequently followed for 3 years by telephone
interview to record institutionalization.
Discussion: There is considerable debate about the clinical and cost effectiveness of anti-dementia
drugs. DOMINO-AD seeks to provide clear evidence on the best treatment strategies for those
managing patients at a particularly important clinical transition point.
Trial registration: Current controlled trials ISRCTN4954503
[McCormick & Co. delivery truck at loading dock]
No full textFrom Sleeve: Bee Brand Mayonnaise. No prints. McCormick & Co inc truck. 1926. A209.Bee Brand Mayonnaise ad on side of truck. Mack truck.Title supplied by cataloger.Positive digital file from original glass negative.Broken into six pieces. Emulsion beginning to chip at the edges
- …
